No­vo Hold­ings picks up in­jecta­bles CD­MO in push for sin­gle-use man­u­fac­tur­ing tech

For 25 years, Rite­dose has been a CD­MO that’s pro­vid­ed ster­ile, asep­tic pro­duc­tion of sin­gle-dose med­ica­tion for more than 8 bil­lion dos­es. No­vo Hold­ings has tak­en no­tice, ac­quir­ing the Co­lum­bia, GA-based com­pa­ny from AG­IC Cap­i­tal and Hu­man­well.

“The in­vest­ment in Rite­dose is per­fect­ly aligned with our deep ex­per­tise in phar­ma ser­vices. We see myr­i­ad op­por­tu­ni­ties to have an im­pact at Rite­dose,” No­vo’s head of prin­ci­pal in­vest­ments Ab­hi­jeet Lele said in a state­ment. “We are al­so par­tic­u­lar­ly ex­cit­ed to be at the van­guard of in­creas­ing vac­cine avail­abil­i­ty through the use of blow-fill-seal in­jectable tech­nol­o­gy.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER